Nachrichten zur Regeneron Pharmaceuticals Inc. Aktie

2 Beaten-Down Stocks to Buy and Hold

Key PointsModerna has a deep pipeline of promising mRNA candidates that stand to boost business.Regeneron is looking at label expansions…

Sanofi und Regeneron erhalten weitere US-Zulassung für Dupixent

DJ Sanofi und Regeneron erhalten weitere US-Zulassung für Dupixent Von Adria Calatayud DOW JONES--Sanofi und ihr Partner Regeneron Pharmaceuticals können…

23andMes founder Anne Wojcicki wins bid for DNA testing firm

Anne Wojcicki is set to regain control of 23andMe after a nonprofit she controls topped Regeneron Pharmaceuticals bid for the…

Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?

Shares of Regeneron (NASDAQ: REGN) have declined this year due to issues with one of its former growth drivers, Eylea,…

Regeneron Pharmaceuticals Aktie: Massives Comeback-Potenzial!

New York (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von J.P. Morgan Securities: JPMorgan habe laut einer am Montag veröffentlichten Studie das Kursziel für…

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript

…

Regeneron Pharmaceuticals Aktie: Kursziel sinkt auf 600 USD wegen schwacher Itepekimab-Daten

Toronto (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von BMO Capital Markets: Die Analysten von BMO Capital Markets stufen die Aktie von Regeneron Pharmaceuticals…

Regeneron Pharmaceuticals Aktie unter Druck - Itepekimab enttäuscht, RBC reagiert mit Abstufung

Toronto (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von RBC Capital Markets: Die Analysten von RBC Capital Markets haben die Aktie von Regeneron Pharmaceuticals…

Regeneron Pharmaceuticals Aktie: Daten-Dilemma! Hoffnung, aber kein klarer Weg

New York (www.aktiencheck.de) - Regeneron Pharmaceuticals der Citigroup: Die US-Großbank Citi habe das Kursziel für die Aktie von Regeneron Pharmaceuticals Inc.…

Regeneron Pharmaceuticals Aktie: Kursziel sinkt nach Studienflop - Analysten sehen dennoch Comeback-Potenzial

Boston, MA (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von Leerink Partners: Die Investmentbank Leerink habe das Kursziel für die Aktie von Regeneron Pharmaceuticals…

The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip

Even though broader equities have been highly volatile this year, its still a good idea to invest in stocks for…

Regeneron-Aktie crasht nach COPD-Daten – Verona Pharma schießt auf Allzeithoch

Bittere Pille für Regeneron Pharmaceuticals. Das Unternehmen und der Entwicklungspartner Sanofi haben in der vergangenen Handelswoche mit frischen Spätphasen-Studiendaten zum…

Regeneron shares plunge after mixed COPD drug trial results

Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) sank nearly 19% on Friday after the company’s experimental COPD drug, developed with partner…

The Company Buying 23andMe Is a Pharmaceutical Giant. Heres How Investors Can Benefit From the Move.

Earlier this year, biotech company 23andMe filed for bankruptcy. The harsh reality was that its business, while enticing to people…

23andMe to delist from Nasdaq, deregister with SEC

Regeneron Pharmaceuticals said earlier this month that it will acquire "substantially all" of 23andMes assets for $256 million.…

Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million

Regeneron is acquiring "substantially all" of 23andMes assets for $256 million following a bankruptcy auction.…

23andMe Sells Gene-Testing Business to DNA Drug Maker Regeneron

Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people,…

Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, the companies said…

Regeneron to buy bankrupt genetic testing firm 23andMe for $256 million

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, the companies said…

Regeneron to buy 23andMe out of bankruptcy for $256m

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has agreed to buy genetic testing company 23andMe for $256 million, two months after the biotech…

2 Unstoppable Dividend Stocks to Buy and Hold Forever

Some research has shown that dividend-paying stocks significantly outperformed their non-dividend-paying peers over the past few decades, and that the…

Regeneron Pharmaceuticals Aktie: Kurzfristige operative Schwächen

New York (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von Oppenheimer: 1. Kurszielanpassung: Oppenheimer hat das Kursziel für die Aktie von Regeneron Pharmaceuticals Inc. (ISIN:…

Regeneron Reports First Quarter 2025 Financial and Operating Results

TARRYTOWN, N.Y., April 29, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for…

Market Sell-Off: 2 Stocks Down 17% and 36% This Year to Buy and Hold

What should investors do during a stock-market correction? One great strategy is to go shopping. A bull market will eventually…

Regeneron signs over $3 billion deal with contract drugmaker to boost US manufacturing

Regeneron Pharmaceuticals said on Tuesday it had entered into a deal valued at more than $3 billion with contract drug…

Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S.…

Is Vertex Pharmaceuticals Stock a Buy?

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex…

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year,…

The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals

Alcon, Glaukos and Regeneron Pharmaceuticals are part of the Zacks top Analyst Blog.…

Why Pharma and Biotech Stocks Got Thrashed on Tuesday

As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative…

Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will…

Lawsuit Notice: Investors who hold Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares should contact the Shareholders Foundation

Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).…

1 Dividend Stock Down 30% to Buy and Hold for the Next Decade

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) saw its fortunes reversed last year. Though the drugmaker had performed well since the…

The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals

Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.…

2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the…

ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…

This Company Just Initiated a Quarterly Dividend: Time to Buy?

Biotech giant Renegeron Pharmaceuticals (NASDAQ: REGN) reported its fourth-quarter and full-year 2024 earnings on Feb. 4. The companys results were…

Regeneron Pharmaceuticals Aktie: Verkaufsdruck übertrieben

New York (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von Guggenheim Securities: Aktuelle Bewertung Die Investmentbank Guggenheim Securities hat ihr Kursziel für die Aktie von…

Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move

Investing in stocks that arent performing well can be a good move, but only if there are good reasons to…

REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Feb. 09, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized…

ROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

NEW YORK, Feb. 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Shareholders that lost money on Regeneron Pharmaceuticals, Inc. (REGN) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc.…

Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

LOS ANGELES, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming…

Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the…

Regeneron beats quarterly estimates on eczema drug demand; launches dividend program

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced…

Regeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion

TARRYTOWN, N.Y., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for…

Regeneron Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; March 10, 2025 Deadline to file Lead Plaintiff Motion

Investors can contact the law firm at no cost to learn more about recovering their losses…

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To…

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…